清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China

弥漫性大B细胞淋巴瘤 医学 内科学 单变量分析 阶段(地层学) 淋巴瘤 B症状 纵隔 癌症 肿瘤科 胃肠病学 病理 放射科 多元分析 生物 古生物学
作者
Yuankai Shi,Ying Han,Jianliang Yang,Peng Liu,Xiaohong He,Changgong Zhang,Shengyu Zhou,Liqun Zhou,Yan Qin,Yong-Wen Song,Yueping Liu,Shulian Wang,Jing Jin,Lin Gui,Yan Sun
出处
期刊:Chinese Journal of Cancer Research [Chinese Journal of Cancer Research]
卷期号:31 (1): 152-161 被引量:64
标识
DOI:10.21147/j.issn.1000-9604.2019.01.10
摘要

To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site.A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.In the 1,085 patients, 679 (62.6%) cases were nodal DLBCL (N-DLBCL) and 406 cases (37.4%) were extranodal DLBCL (EN-DLBCL). The most common sites of N-DLBCL were lymphonodus (64.8%), Waldeyer's ring (19.7%), mediastinum (12.8%) and spleen (2.7%), while in EN-DLBCL, stomach (22.4%), intestine (16.0%), nose and sinuses (8.9%), testis (8.4%), skin (7.9%), thyroid (6.9%), central nervous system (CNS) (6.4%), breast (5.7%), bone (3.4%), and salivary gland (2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival (OS) rate and progression-free survival (PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9% (P=0.008), and the 5-year PFS were 57.0% and 49.0% (P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate (83.6%) and PFS rate (76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach, breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%, respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17秒前
20秒前
郭晨发布了新的文献求助10
24秒前
胡杨树2006完成签到,获得积分10
25秒前
滕皓轩完成签到 ,获得积分10
31秒前
32秒前
柒八染完成签到 ,获得积分10
34秒前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
xiazhq完成签到,获得积分10
1分钟前
tmobiusx完成签到,获得积分10
1分钟前
1分钟前
上官若男应助lt0217采纳,获得10
1分钟前
2分钟前
淞淞于我完成签到 ,获得积分10
2分钟前
jason完成签到 ,获得积分10
2分钟前
华仔应助mmyhn采纳,获得10
2分钟前
chichenglin完成签到 ,获得积分10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
CipherSage应助科研通管家采纳,获得10
3分钟前
秋夜临完成签到,获得积分10
3分钟前
3分钟前
gobi完成签到 ,获得积分10
3分钟前
CHEN完成签到 ,获得积分10
3分钟前
huiluowork完成签到 ,获得积分10
4分钟前
田田完成签到 ,获得积分10
4分钟前
含蓄的问寒完成签到,获得积分10
4分钟前
平平安安完成签到 ,获得积分10
4分钟前
平平安安关注了科研通微信公众号
4分钟前
mmyhn发布了新的文献求助10
4分钟前
稳重傲晴完成签到 ,获得积分10
5分钟前
5分钟前
mmyhn发布了新的文献求助10
5分钟前
玛琳卡迪马完成签到,获得积分10
5分钟前
青出于蓝蔡完成签到,获得积分10
5分钟前
5分钟前
mmyhn发布了新的文献求助10
5分钟前
5分钟前
xun完成签到,获得积分20
5分钟前
zijingsy完成签到 ,获得积分10
6分钟前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2500
Востребованный временем 2500
Aspects of Babylonian celestial divination : the lunar eclipse tablets of enuma anu enlil 1500
Agaricales of New Zealand 1: Pluteaceae - Entolomataceae 1040
Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation 1000
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
体心立方金属铌、钽及其硼化物中滑移与孪生机制的研究 800
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 纳米技术 内科学 物理 化学工程 计算机科学 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 电极
热门帖子
关注 科研通微信公众号,转发送积分 3450460
求助须知:如何正确求助?哪些是违规求助? 3045952
关于积分的说明 9003759
捐赠科研通 2734604
什么是DOI,文献DOI怎么找? 1500096
科研通“疑难数据库(出版商)”最低求助积分说明 693341
邀请新用户注册赠送积分活动 691477